GLP1 Receptor Agonists-Effects beyond Obesity and Diabetes.
Sydney S WilbonMikhail G KoloninPublished in: Cells (2023)
Glucagon-like peptide-1 receptor agonists (GLP1RA) have been transformative for patients and clinicians in treating type-2 diabetes and obesity. Drugs of this class, the bioavailability of which is continuously improving, enable weight loss and control blood glucose with minimal unwanted side effects. Since adopting GLP1RA for treating metabolic diseases, animal and clinical studies have revealed their beneficial effects on several other pathologies, including cardiovascular diseases, neurodegeneration, kidney disease, and cancer. A notable commonality between these diseases is their association with older age. Clinical trials and preclinical data suggest that GLP1RA may improve outcomes in these aging-related diseases. Some of the benefits of GLP1RA may be indirect due to their effects on obesity and glucose metabolism. However, there is building evidence that GLP1RA may also act directly on multiple organs implicated in aging-related pathology. This review aims to compile the studies reporting the effects of GLP1RA on aging-related diseases and discuss potential underlying mechanisms.
Keyphrases
- type diabetes
- weight loss
- rheumatoid arthritis
- glycemic control
- blood glucose
- insulin resistance
- disease activity
- cardiovascular disease
- metabolic syndrome
- clinical trial
- ankylosing spondylitis
- bariatric surgery
- weight gain
- high fat diet induced
- end stage renal disease
- roux en y gastric bypass
- interstitial lung disease
- randomized controlled trial
- palliative care
- newly diagnosed
- blood pressure
- systemic lupus erythematosus
- single cell
- stem cells
- gastric bypass
- adipose tissue
- skeletal muscle
- chronic kidney disease
- squamous cell carcinoma
- young adults
- electronic health record
- cardiovascular risk factors
- patient reported outcomes
- community dwelling
- artificial intelligence
- childhood cancer